Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2016

Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2016


  • Products Id :- GMDHC8352IDB
  • |
  • Pages: 102
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2016', provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections

The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects

The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Influenza A Virus, H3N2 Subtype Infections Overview 10

Therapeutics Development 11

Pipeline Products for Influenza A Virus, H3N2 Subtype Infections-Overview 11

Pipeline Products for Influenza A Virus, H3N2 Subtype Infections-Comparative Analysis 12

Influenza A Virus, H3N2 Subtype Infections-Therapeutics under Development by Companies 13

Influenza A Virus, H3N2 Subtype Infections-Therapeutics under Investigation by Universities/Institutes 15

Influenza A Virus, H3N2 Subtype Infections-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Influenza A Virus, H3N2 Subtype Infections-Products under Development by Companies 19

Influenza A Virus, H3N2 Subtype Infections-Products under Investigation by Universities/Institutes 21

Influenza A Virus, H3N2 Subtype Infections-Companies Involved in Therapeutics Development 22

AbbVie Inc 22

AIMM Therapeutics B.V. 23

Aphios Corporation 24

Celltrion, Inc. 25

FluGen, Inc. 26

Glide Pharmaceutical Technologies Limited 27

ILiAD Biotechnologies, LLC 28

Inovio Pharmaceuticals, Inc. 29

Johnson & Johnson 30

Medicago Inc. 31

MedImmune, LLC 32

Mucosis B.V. 33

NanoViricides, Inc. 34

OPKO Health, Inc. 35

Sarepta Therapeutics, Inc. 36

Takeda Pharmaceutical Company Limited 37

VBI Vaccines Inc. 38

Visterra, Inc. 39

Zydus Cadila Healthcare Limited 40

Influenza A Virus, H3N2 Subtype Infections-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Combination Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

APP-0205-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

APP-309-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Aspidasept-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

C-05-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

CR-8020-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

CR-9114-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

CTP-27-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Fluad (quadrivalent)-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

FluGEM-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Gamma-Flu-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

influenza [strain A/H3N2] (monovalent) vaccine-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

influenza [strain A/H3N2] vaccine-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

influenza [strain A/H3N2] vaccine-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

influenza [strain A/H3N2] vaccine-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

JNJ-872-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

NEO-8877-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

NVINF-1-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

NVINF-2-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

pertussis [strain BPZE1] vaccine-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

PNSIA-28-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

radavirsen-Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

REDEE FLU-Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

Small Molecules for RSV and Influenza A Infections-Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

VIS-410-Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects 97

Influenza A Virus, H3N2 Subtype Infections-Product Development Milestones 98

Featured News & Press Releases 98

Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season 98

Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 98

Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 99

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 101

Disclaimer 102

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2016 11

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AbbVie Inc, H2 2016 22

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AIMM Therapeutics B.V., H2 2016 23

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Aphios Corporation, H2 2016 24

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Celltrion, Inc., H2 2016 25

Influenza A Virus, H3N2 Subtype Infections-Pipeline by FluGen, Inc., H2 2016 26

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016 27

Influenza A Virus, H3N2 Subtype Infections-Pipeline by ILiAD Biotechnologies, LLC, H2 2016 28

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 29

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Johnson & Johnson, H2 2016 30

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Medicago Inc., H2 2016 31

Influenza A Virus, H3N2 Subtype Infections-Pipeline by MedImmune, LLC, H2 2016 32

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Mucosis B.V., H2 2016 33

Influenza A Virus, H3N2 Subtype Infections-Pipeline by NanoViricides, Inc., H2 2016 34

Influenza A Virus, H3N2 Subtype Infections-Pipeline by OPKO Health, Inc., H2 2016 35

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Sarepta Therapeutics, Inc., H2 2016 36

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 37

Influenza A Virus, H3N2 Subtype Infections-Pipeline by VBI Vaccines Inc., H2 2016 38

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Visterra, Inc., H2 2016 39

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Zydus Cadila Healthcare Limited, H2 2016 40

Assessment by Monotherapy Products, H2 2016 41

Assessment by Combination Products, H2 2016 42

Number of Products by Stage and Target, H2 2016 44

Number of Products by Stage and Mechanism of Action, H2 2016 46

Number of Products by Stage and Route of Administration, H2 2016 48

Number of Products by Stage and Molecule Type, H2 2016 50

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects, H2 2016 97

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2016 11

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 41

Assessment by Combination Products, H2 2016 42

Number of Products by Targets, H2 2016 43

Number of Products by Stage and Targets, H2 2016 43

Number of Products by Mechanism of Actions, H2 2016 45

Number of Products by Stage and Mechanism of Actions, H2 2016 45

Number of Products by Routes of Administration, H2 2016 47

Number of Products by Stage and Routes of Administration, H2 2016 47

Number of Products by Molecule Types, H2 2016 49

Number of Products by Stage and Molecule Types, H2 2016 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

AIMM Therapeutics B.V.

Aphios Corporation

Celltrion, Inc.

FluGen, Inc.

Glide Pharmaceutical Technologies Limited

ILiAD Biotechnologies, LLC

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Medicago Inc.

MedImmune, LLC

Mucosis B.V.

NanoViricides, Inc.

OPKO Health, Inc.

Sarepta Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

VBI Vaccines Inc.

Visterra, Inc.

Zydus Cadila Healthcare Limited

Influenza A Virus, H3N2 Subtype Infections Therapeutic Products under Development, Key Players in Influenza A Virus, H3N2 Subtype Infections Therapeutics, Influenza A Virus, H3N2 Subtype Infections Pipeline Overview, Influenza A Virus, H3N2 Subtype Infections Pipeline, Influenza A Virus, H3N2 Subtype Infections Pipeline Assessment

select a license
Single User License
USD 2000 INR 143580
Site License
USD 4000 INR 287160
Corporate User License
USD 6000 INR 430740

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com